Articles tagged with Breast Cancer
The Notch pathway plays a crucial role in regulating breast stem cell fate, controlling both stem cell number and the production of luminal cells. Errant activation of Notch leads to uncontrolled growth of luminal precursors, resulting in breast tumour formation.
Four recipients of the ASPS Patients of Courage award have undergone extensive reconstructive plastic surgeries to restore their appearance. Erin Williams, Rachel Cooney, Missy Fish, and Sgt. Robert Bartlett use their experiences to help others struggling with life's obstacles.
A study published in the Journal of the National Cancer Institute found that tamoxifen treatment may advance detection of ER-negative breast cancer in high-risk women, shortening the time to diagnosis by approximately 1 year. The drug does not alter the risk of ER-positive disease.
A large review of 38 studies found regular NSAID use associated with reduced breast cancer risk. Aspirin and Advil showed significant protective effects, with a 13-21% relative risk reduction.
Researchers propose a nested case-control study design called PRoBE to evaluate biomarker classification accuracy, minimizing bias. Regular NSAID use is associated with a 12% relative risk reduction in breast cancer risk, according to a meta-analysis of 38 studies involving 2,788,715 women.
Researchers discovered that tamoxifen can reduce the median time to diagnosis of ER-negative breast cancer by a year, improving detection rates through mammography. The study suggests an unexpected link between tamoxifen use and earlier disease identification in high-risk patients.
Researchers at University of Missouri are studying the interactions between black cohosh and tamoxifen in a unique rat model to understand its safety and effectiveness. The goal is to provide reliable information on how women can use herbal supplements to enhance their breast cancer treatment and improve quality of life.
The new guidelines provide a tiered system of resource allocation to implement early detection, diagnosis, and treatment programs. The initiative aims to improve breast health outcomes in low- and middle-income countries, where cancer mortality rates are highest.
A study of 215 women who underwent BRCA testing found that personal beliefs about inconclusive results are a strong predictor of psychological adjustment. Women with higher levels of worry and distress were more likely to struggle with the uncertainty of their test results.
A study found that birth weight is associated with an increased risk of breast cancer later in life, particularly among women living in developed countries. The analysis of over 600,000 women revealed a 7% increase in risk for every 0.5 kg increment in birth weight.
Researchers developed a new MRI technique that can detect tiny breast cancers, including ductal carcinoma in situ (DCIS), in mice. The method has shown promising results in detecting small tumors less than 300 microns in diameter and distended milk ducts with cancer.
A new study published in PLOS Medicine found that birth size is a significant marker of susceptibility to breast cancer later in life. The research analyzed data from over 600,000 women and discovered that a 0.5 kg increase in birth weight was associated with a 7% higher risk of breast cancer. Birth length and head circumference were a...
A study analyzing English cancer patients found that cervical and lung cancer rates are higher among poor people, while breast and melanoma rates are higher in wealthier groups. Smoking is strongly associated with socioeconomic status and contributes to the higher incidence of lung cancer in deprived groups.
A retrospective study found that women with 3 or fewer involved lymph nodes have a low relapse rate after undergoing pre-operative chemotherapy and mastectomy. Patients with zero involved lymph nodes had a zero percent recurrence rate.
A new predictive measurement, called a PEPI score, can help determine the treatment of breast cancer patients. A low PEPI score indicates little risk of relapse and allows patients to safely avoid chemotherapy after surgery. Women with high PEPI scores are at high risk of having their cancer return and require aggressive therapy.
Research finds activation of Src signaling pathway contributes to treatment resistance in some patients with triple-negative breast cancer. Inhibiting this pathway holds promise as a way to overcome resistance and improve patient outcomes.
The breast cancer incidence in China is expected to increase due to lifestyle changes and adoption of Western lifestyles. Researchers predict a total of 2.5 million cases by 2012, with modifications to lifestyle and reproductive risk factors potentially preventing 270,000 cases.
Researchers developed a preoperative endocrine prognostic index (PEPI) to predict relapse risk in women with stage 2 or 3 estrogen receptor-positive breast cancer. The model incorporates tumor characteristics and is statistically significant in predicting relapse-free survival.
A recent observational study published in the Journal of the National Cancer Institute suggests that hormone therapy may be safe for postmenopausal women with BRCA mutations. The study found a 42% relative reduction in breast cancer risk among women who used hormone therapy, although further research is needed to confirm these findings.
A study found that genistein, a soy-based dietary supplement, can negate the effectiveness of aromatase inhibitors used to treat post-menopausal breast cancer. The researchers observed a dose-dependent reduction in treatment efficacy, leading to tumor growth.
A new report shows that racial disparities in cancer incidence are declining in Missouri, with the gap narrowing between African Americans and whites. However, racial disparities in cancer death rates remain higher for African Americans, despite efforts to reduce them.
A new type of accelerated partial breast irradiation (APBI) called balloon brachytherapy is as effective in keeping breast cancer from coming back as standard external beam radiation. This shorter treatment option makes radiation therapy more convenient for patients, potentially increasing the rate of breast conservation.
A randomized study found that accelerated hypofractionated whole breast irradiation is as effective as standard five-week treatment in reducing local recurrence and side effects. The new therapy reduces the radiation time to three weeks, resulting in a cost savings of two-thirds compared to traditional treatment.
A randomized clinical trial shows acupuncture reduces hot flashes and vasomotor symptoms in breast cancer patients, providing additional benefits like increased energy and well-being. The treatment has no side effects compared to commonly used drugs.
A study by Fox Chase Cancer Center found that breast cancer survivors reported a high level of overall quality of life several years after treatment, with some improvements over time. The survey tool used measured health outcomes using the EQ-5D instrument and compared results to a general US adult population.
A new study suggests that breast MRI scans can help determine if women scheduled to undergo surgery will later need radiation therapy. The research found that tumors' physiological information shown on MRI scans correlated with surgically based findings of cancer having spread to lymph nodes.
Researchers at the University of Toronto have discovered that two protein cousins, related to the p53 family, play a critical role in cancer development. The findings challenge traditional thinking and suggest a new branch of scientific inquiry into cancer development.
A new advance in cellular imaging allows scientists to track the movement of live cells in the area around tumors, providing insights into how certain immune cells help or hinder tumor growth. This study sheds light on potential drug targets and mechanisms to enhance the body's natural immune response to cancer.
Studies in mice reveal that women who have children young have fewer mammary stem cells, which could contribute to lower breast cancer risk. Researchers plan to investigate further to determine the mechanism behind this protective effect and explore potential treatments.
Researchers found that adding four cycles of Taxotere to a sequential regimen of epirubicin and cyclophosphamide, methotrexate and fluorouracil reduces recurrence and death rates in patients with node-positive early stage breast cancer. This advantage comes at an increased toxicity level.
Researchers found that computer models underpredicted BRCA mutation frequency in Asian-American women by 50% compared to Caucasian counterparts. This suggests that more women of Asian descent may be at increased risk of hereditary breast and ovarian cancers than previously believed.
Regular breast cancer screening programs in developed countries show promise for reducing mortality in India. A new study estimates that annual or biennial clinical breast exams can lower mortality rates by 8.2% and gain life years at a cost-effectiveness of $1,135 per life-year gained.
A study adjusting for a known bias in familial melanoma risk estimates reveals an increased relative risk of 3.18, with higher risks for young-onset cases. In contrast, the risks for colorectal, lung, breast, and prostate cancer remain relatively stable.
Researchers found that anti-angiogenic drugs block chemotherapy-induced blood vessel formation, thereby hindering tumor regrowth. This mechanism may explain why some chemotherapy combinations enhance treatment efficacy.
Australian scientists identified four groupings of genes related to breast cancer cell behavior and their impact on tamoxifen treatment. This discovery could help clinicians predict which women will respond well to anti-oestrogen therapies.
A new study suggests that routine use of MRI scans in women with newly-diagnosed breast cancer may lead to delays in treatment and an increase in mastectomies. The study found that younger women were more likely to receive MRIs, but failed to improve surgical outcomes.
A new treatment strategy involving sorafenib could 're-sensitize' tumors, enabling anti-hormonal drugs like aromatase inhibitors to be effective again. Preliminary analysis shows a clinical benefit response in 26 percent of patients taking both sorafenib and anastrozole.
The study identifies frequently mutated genes, including ERBB2 and NF1, which were previously underestimated in their role in glioblastoma. The analysis also provides a wide view of how cell pathways are altered during the initiation and growth of glioblastoma, offering insights into strategies to diagnose and treat the disease.
A nationwide study found that black women are less likely than white women to receive standard radiation therapy after a lumpectomy, with significant regional variations. The disparity affects over 37,000 patients and highlights the need for further research into underlying reasons and potential barriers to care.
Researchers at M.D. Anderson Cancer Center discovered that 50% of HER2-positive breast cancer patients showed no signs of disease after surgery treated with Herceptin. However, some patients developed tumors that converted from HER2 positive to negative status, suggesting potential resistance to the therapy.
A substudy of the IBIS II trial found no significant differences in cognitive assessments between postmenopausal women receiving anastrozole and placebo, but noted more endocrine symptoms such as hot flushes in the anastrozole group.
Researchers found that IGF-I stimulates aggressive tumor growth and DNA repair regulation, leading to poor outcomes. The study identifies a gene signature linked to patient responses to breast cancer treatments, offering potential biomarkers for targeted therapies.
Researchers at Cold Spring Harbor Laboratory discovered an enzyme called Brk that accelerates HER2-positive tumor growth and contributes to drug resistance. The team found that targeting Brk may provide a safe strategy for treating ErbB2-positive tumors.
A study found that reproductive and hormonal factors influence the risk of developing different subtypes of breast cancer. Breastfeeding for 6 months or longer was associated with a lower risk of luminal and triple-negative cancers, while late age at menopause and estrogen therapy were linked to increased risks.
A prospective cohort study of 6107 Chinese patients with type 2 diabetes found a V-shaped risk relation between LDL cholesterol and cancer. Patients with low LDL cholesterol (below 2.80 mmol/L) or high levels (above 3.90 mmol/L) had significantly elevated risks of various cancers.
A recent study published in BMC Cancer found that women who experienced multiple negative life events are at a higher risk of developing breast cancer. The research, conducted by Professor Ronit Peled and her team, suggests that a general feeling of happiness and optimism can play a protective role against the disease.
Research finds that dense breast tissue promotes aggressive cancer cells, as breast cancer cells in denser surroundings step up their invasive activities. The study suggests a cellular mechanism linking human breast tissue density and tumor aggressiveness.
A study by Deborah A. Small and Uri Simonsohn found that people become more sympathetic towards victims suffering from the same misfortune as a close relationship, leading to increased donations to charities supporting those causes. The researchers recreated this phenomenon in an experiment where participants formed new friendships and...
A new study found that young women with positive emotional states and high levels of happiness are less likely to develop breast cancer. However, women who have experienced multiple severe or mild negative life events are at higher risk for the disease. The researchers suggest that a general feeling of happiness can play a protective r...
Concomitant zoledronic acid prevents bone loss and improves bone-mineral density in premenopausal women with breast cancer during adjuvant endocrine therapy. After treatment, zoledronic acid even increases bone-mineral density.
Despite five years of systemic therapy, breast cancer patients remain at risk for disease recurrence. Women with hormone receptor-positive cancer have a higher risk of relapse, highlighting an unmet clinical need for new strategies to reduce this risk.
Researchers identified specific HBV genotypes and mutations associated with increased liver cancer risk, including genotype C and basal core promoter mutation A1762T/G1764A. A combination of doxorubicin and zoledronic acid was found to reduce tumor size substantially in a mouse model of breast cancer.
A study led by M. D. Anderson Cancer Center found that risk assessment can help determine the probability of breast cancer recurrence, allowing clinicians to make informed decisions about extended therapy. The research analyzed data from 2,838 women diagnosed with Stage I-III breast cancers and treated with adjuvant systemic therapy.
Researchers at the University of Chicago Medical Center found that targeted radiation therapy can eradicate all signs of disease in up to 21% of patients with stage-IV cancer who have only a few sites of metastasis. The treatment was well-tolerated, with limited side effects, and showed promising results in controlling tumor growth.
Research reveals that breast cancer survivors must navigate the vulnerabilities of loved ones as they share their diagnosis. Women typically face challenges in asking for help from others while also being perceived as caregivers.
Minority women were significantly less likely to be aware of their odds of survival after five years, regardless of surgeon volume or hospital setting. Women who asked about treatment options had better knowledge, highlighting the need for clear communication from surgeons.
A new study finds that patient age, predisposition to heart disease, and prior treatments are associated with an individual's risk of developing heart problems following epirubicin treatment. The researchers recommend lowering the cumulative dose recommended for most patients, with maximum doses ranging from 300 mg/m2 to 900 mg/m2.
A study comparing two breast cancer screening strategies in Norway and Vermont found that both approaches were equally sensitive for detecting cancer, with similar age-adjusted screening detection rates. However, the recall rate for abnormal mammograms was lower in Norway, while the rate of interval cancers was higher in Vermont.
A recent study published in the American Cancer Society's journal found that hip bone mineral density can provide additional information for predicting breast cancer risk. Women with higher bone mineral density scores had a 25% increased risk of developing breast cancer, while those with high Gail scores had a 35% increased risk.
A study of 10,000 postmenopausal women found that higher bone mineral density was associated with a 25% increased risk of developing breast cancer. Adding bone mineral density tests to current risk assessments may improve the prediction of breast cancer risk in older women.